The future of human longevity: new approaches to healthcare and cancer

20 Sep 2012

Location: Singapore-ETH Centre (SEC), Singapore

About the event

Swiss Re, one of the world’s largest re/insurers, in collaboration with swissnex Singapore, one of five Swiss science and technology consulates worldwide, cordially invite you to this interactive half-day conference, to be held at the Future Cities Laboratory at the Singapore-ETH Centre (SEC) in Singapore.


Thirty years ago, the actuarial tables did not predict we would live this long. That has repercussions, particularly when combined with a low birth rate. Swiss Re is seeking to improve understanding of future longevity trends. As such, we will be addressing two major influences on the length of life:

  • Effective healthcare has clear benefits for the extension of life. Leading experts will focus on the provision of health care, its implementation and covering its cost
  • Cancer is one of the leading causes of death in Asia. We will discuss some of the latest developments in cancer research, from cost-effectiveness, genealogical and epidemiological perspectives

Target audience

Swiss Re insurance industry clients heading mortality and longevity research / pricing unit, and leading experts in fields spanning epidemiology, the aging process, and cutting edge advances in the prevention, detection and treatment of disease.

Note: This event may be photographed, filmed and /or recorded. A summary of the event, pictures and/or a video of the event in which you may appear may be posted and made available on Swiss Re’s and swissnex Singapore's internal and external websites and in printed materials.


Thursday, 20 September 2012

Time difference compared to Central European Time: -6 hours


Welcome coffee and registration


Suzanne Hraba-Renevey, Director, swissnex Singapore
Christopher Lee, Head Client Markets Life & Health, Swiss Re


The impact behaviour has on the prevalence of cancer
John Schoonbee, Chief Medical Officer, Swiss Re


From health policy to implementation into clinical practice
David Matchar, Inaugural Director and Professor, Program in Health Services and Systems Research, Duke-NUS


Coffee break


Cost-effectiveness in cancer care
Helen Chung, Head of Health Policy Research, Swiss Re


Personalised medicine - novel cancer diagnostics and treatment
Christoph Nabholz, Head Business Development, Swiss Re Centre for Global Dialogue


Cancer in Asia
CHIA Kee Seng, Professor and Dean of Saw Swee Hock School of Public Health, National University of Singapore and Director, Centre for Molecular Epidemiology; Adjunct Professor of Epidemiology, Karolinska Institutet, Sweden


Closing remarks
Christopher Lee, Head Client Markets Life & Health, Swiss Re


Networking reception